source
- Eli Lilly inks up to $5.9 billion partnership with Stipple Bio to develop cancer therapiesEli Lilly announced a new collaboration with Cambridge-based biotech Stipple Bio, valued at up to $5.9 billion, aimed at creating novel cancer medicines. The agreement gives Lilly access to Stippl…
- Helus Pharma reports Phase 3 depression trial shows symptom improvement but safety concerns lingerHelus Pharma, a psychedelics-focused company, announced results of its Phase 3 trial for its lead depression drug. The trial showed the drug produced greater improvement in depression symptoms com…